Background: The signal transducer and activator of transcription 3 (STAT3) pathway
| INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed cancer in men and is the second leading cause of death from cancer in men. 1 At diagnosis, PCa is usually confined to the prostate and less than onethird of patients will actually die from the PCa. 1 An increasing number of men with localized PCa are being followed by active surveillance, or being offered curative treatment with radical prostatectomy or radiation therapy at disease progression. 2 To optimize active surveillance, there is a need to identify, at an early stage, those patients who are at a lower risk of developing a more advanced disease and would not benefit from invasive treatments.
New prognostic biomarkers are therefore necessary.
The transcription factor signal transducer and activator of transcription 3 (STAT3) is an important oncogenic-associated protein and found to be constitutively activated by phosphorylation in several malignancies including PCa. [3] [4] [5] [6] [7] [8] STAT3 is activated by a number of inflammatory cytokines such as interleukin 6 (IL-6), IL-10, IL-11, and IL-21. Other factors secreted within the tumor, such as vascular endothelial growth factor, epidermal growth factor, and platelet-derived growth factor may also activate STAT3. 9, 10 High serum levels of IL-6 in PCa patients have been implicated in lower survival rates. 11 Activation of STAT3 by phosphorylation on the 705 tyrosine or the 727 serine has been observed to be involved in cancer progression and a more aggressive phenotype of PCa. 12 However, STAT3 may in certain contexts act as a tumor suppressor 10 and new evidence is emerging showing antioncogenic roles of the STAT3-IL-6 pathway in PCa. 13 The studies investigating the expression patterns of total STAT3
(tSTAT3) and phosphorylated STAT3 (pSTAT3 727 
| Dublin cohort
The TMA was constructed in a similar way to that described above from 99 PCa patients who underwent open radical prostatectomy The final number of patients used in the present study was 99 and the number of patients with BCR (n = 48) was matched with patients with no BCR (n = 51). The study has been approved by the Local Ethic's committee reference number 1/378/660.
| Immunohistochemistry
Tissue sections were cut in 4 µM sections from paraffin blocks and mounted onto slides. Sections underwent preprocessing where they were deparaffinized with xylene and ethanol followed by rehydration and antigen retrieval. Antigen retrieval of the tissue sections was performed using a PT-Link module (DAKO, Glostrup, Denmark) at 95°C
to 99°C for 20 minutes (pH 9.0). The sections were then stained in a DAKO Autostainer-plus using the EnVision FLEX including Peroxidase- Controls were performed to verify the antibody specificity ( Figure S1 ).
The p63/AMACR double staining allowed specific identification of 
| Scoring procedure
Slides were scanned using an Aperio CS2 slide scanner and images were viewed on the Aperio ImageScope Software (Leica Biosystems, Wetzlar,
, and p63/AMACR immunostainings in consecutive sections of benign cores and cores with Gleason pattern 3 (GS3) and 5 (GS5). Scale bar = 100 µm. AMACR, α-methyl acyl-CoA racemase; pSTAT3, phosphorylated STAT3; STAT3, signal transducer and activator of transcription 3; tSTAT3, total STAT3 Germany). The intensity of the nuclear and cytoplasmic staining in the glandular epithelial cells was manually recorded as a score between 0 and 3 (zero, low, moderate, and high; Figure S2 ) and the percent of nuclei stained was also recorded (<10% = 1, 11-75% = 2, >75% = 3). The intensity score and the fraction of positively stained cells were multiplied to give a final score (H score, 0-9, adapted from Detre et al 17 ) that was then used as a representation of expression level in each given patient. A consensus between the scorer (AK) and an experienced pathologist (FM) was reached before the scoring. The results were based on the average score of two benign and two cancer cores from each patient in the Malmö cohort. For the Dublin cohort, the average of three benign cores and up to six cancer cores per patient was used. In the case of missing cores, the score of one core was used.
For Figures 2B, 2D and 2F; 3B and 3D; 4B, 4D and 4F; 5B and 5D, the analysis was done on a per-core basis.
| Statistical analysis
Statistical analysis was performed using SPSS (IBM, Armonk, NY) and R (The R Foundation, https://www.r-project.org/). The mean intensity scores of the benign and cancer cores were compared using the , the H score progressively decreased with increasing Gleason score ( Figure 2D and 2F, ANOVA on ranks).
Cytoplasmic expression was observed only for tSTAT3 and pSTAT3 727 and not for pSTAT3 705 ( Figure 3 ). tSTAT3 showed lower average cytoplasmic expression in cancer cores, compared with benign cores from the same patients (the Wilcoxon signed-rank test, P < 0.05; Figure 3A ). There was no significant difference in pSTAT3 727 expression between benign and cancer ( Figure 3C ), but, when stratified according to Gleason score, higher expression was observed for pSTAT3 727 in GS < 7 cores (ISUP grade 1; Figure 3D , ANOVA on ranks).
| Dublin cohort
The nuclear expression of the three markers followed a similar pattern in the Dublin cohort, in that the H score in the cancer cores was lower than in the benign cores ( Figure 4 ). When comparing benign and cancer cores from the same patient, only the difference in tSTAT3 expression was significant ( Figure 4A , P < 0.001, the
Wilcoxon signed-rank test, n = 96). There was a tendency for the pSTAT 727 H score to be lower in the cancer cores ( Figure 4C , P = 0.076, the Wilcoxon signed-rank test, n = 96). Stratifying the cores according to their Gleason score, showed a progressive decrease in nuclear expression intensities for all three markers in the higher Gleason scores ( Figure 4B , 4D, and 4F, ANOVA on ranks).
As in the Malmö cohort, only tSTAT3 and pSTAT 727 showed cytoplasmic staining. There was a significant difference between benign and cancer cores from the same patient for cytoplasmic tSTAT3
(P = 0.04, the Wilcoxon signed-rank test, n = 96; Figure 5A ), but there were no significant differences amongst the different Gleason scores. Table 2 shows correlations (Spearman correlation, r s ) between the different markers in both nucleus and cytoplasm. Moderate correlation was assumed to be above 0.5 and high above 0.7. 18 We observed high correlations between nuclear pSTAT3 727 and pSTAT3 705 
| Correlations

| Outcome analysis
Nuclear and cytoplasmic tSTAT3 expression in the Malmö cohort was not predictive of BCR progression ( Figure 6A and 6B). However, in KRZYZANOWSKA ET AL. the Dublin cohort, patients with higher cytoplasmic tSTAT3 had a shorter time to BCR (P < 0.001, Figure 7B ).
For Malmö pSTAT3
727
, both low nuclear ( Figure 6C ) and low cytoplasmic ( Figure 6D ) expression predicted worse outcome (P < 0.001 and P < 0.05). Similar patterns were observed in the Dublin cohort, although they did not reach significance ( Figure 7C and 7D ).
Malmö patients with low pSTAT3 705 nuclear expression in the cancer gland epithelial cells had a shorter time to BCR (P < 0.001; Figure   6E ). The Dublin data followed the same trend ( Figure 7E , P = 0.08).
No significant predictive trends were observed for any of the three markers in benign cores (data not shown).
Survival analysis based on pathological tumor (pT) stage produced Kaplan-Meier curves which demonstrated that patients with pT2 had longer time to BCR compared with pT3 in both cohorts ( Figure S3A and SC). Survival benefit was also seen in relation to pGS at radical prostatectomy in the Malmö cohort-lower pGS resulted in longer time to BCR ( Figure S3B and SD).
In the Malmö cohort, pGS and pT were predictive of progression (Table 3) . Nuclear pSTAT3 727 and pSTAT3 705 in the cancer cores were also predictive (P < 0.05, Table 3 ) but multivariable analysis of these markers did not improve the prognostic value of pGS or pT stage. In the Dublin cohort, pGS, pT and cytoplasmic tSTAT3 were predictive of progression (P < 0.05, Table 3 ). Multivariable analysis did not improve the prognostic value of pGS or pT stage.
| DISCUSSION
In the present study we examined tSTAT3, pSTAT3 Moreover, our data indicated that the patients with the lower nuclear and cytoplasmic pSTAT3 727 and nuclear pSTAT3 705 expression in the cancer cores had shorter time to BCR and therefore worse prognosis. Our data is in line with findings that total tSTAT3 protein expression decreases with increasing Gleason scores 13 and that pSTAT3 727 expression is lower in patients with higher pT stages. 19 However, all of the above is in contrast to previous reports where an increase of pSTAT3 727 and pSTAT3 705 in cancerous tissue was observed [20] [21] [22] [23] [24] and high that pSTAT3 levels were indicative of disease Dark blue indicates correlation coefficient of >0.7, light blue, correlation coefficient of >0.5.
*P < 0.05. **P < 0.01. ***P < 0.001-Spearman correlation coefficient. suggested to function as a tumor suppressor and a negative regulator of STAT3α which has mainly tumor promoting activities. 32 In the current study we cannot differentiate STAT3α from STAT3β with the antibodies used. In a study of esophageal squamous cell carcinoma, high pSTAT3α was correlated to longer overall survival, but in combination with low pSTAT3β, the outcome was worse.
33
It is also important to consider that coexpression of STAT3 with other intracellular mediators may be of clinical interest. 34 Pencik et al 13 showed that low tSTAT3 was correlated with a poor outcome, which was worse if combined with low p14 ARF expression. Similarly, studies in glioblastoma found that pSTAT3 can have pro-oncogenic or tumor-suppressive functions depending the presence of PTEN. As a control for the cohort, we examined the prognostic values of pathologic GS and pT stage. In the Malmö cohort they both correlated with survival, showing that those two are the best prognostic markers for BCR. In the Dublin cohort, while the pT stage showed expected BCR patterns, the pGS was not prognostic of BCR. This discrepancy is likely to be the result of the patients being selected and matched in the Dublin cohort, resulting in a 49% rate of BCR, which is unnaturally high for a normal, unselected population. This may explain some of the differences between the cohorts although it is impossible to tell how much these factors influence the results. It is very difficult to obtain similar material from different centers.
pGS and pT stage, together with factoring in the patients age, provide good models for BCR prediction. Adding our results of epithelial tSTAT3 and pSTAT3 expression lowered the prognostic value of pGS and pT stage, and therefore pSTAT3 expression is unlikely to be beneficial as a prognostic marker in hormone naïve localized PCa (Table 3) . 
| CONCLUSIONS
